ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Start-ups

Confo raises $33.4 million for GPCR antibodies

by Ryan Cross
May 18, 2019 | APPEARED IN VOLUME 97, ISSUE 20

 

Confo Therapeutics, a Belgian start-up, has raised $33.4 million in series A financing from a suite of venture capital firms that includes Biogeneration Ventures and Wellington Partners. Confo is developing single-domain antibodies—sometimes called nanobodies—that are derived from camels. It plans to use the antibodies to target specific conformations of G protein–coupled receptors, a protein class involved in many nervous-system functions. Confo has partnerships with Lundbeck and Roche.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment